YHP2205

YHP2205 is an orally administered small molecule drug developed by Yuhan Corporation. It is a new molecular entity currently in phase 1 clinical trials, primarily studied for bioequivalence in healthy volunteers. The specific mechanism of action and therapeutic indication remain undisclosed as of the latest updates. Clinical studies have compared its pharmacokinetics to those of another compound, YHR2401, with endpoints focused on parameters such as area under the plasma concentration-time curve and maximum plasma concentration for edoxaban, suggesting a possible relationship to anticoagulant therapy or similar pharmacological class; however, this has not been explicitly confirmed in public sources[1][3][4][7].